PD Neurotechnology

PD Neurotechnology operates at the intersection of medical devices, neuroscience, digital health, and remote patient monitoring. Its focus is narrower than broad wearable-health platforms because PDMonitor® is designed specifically for Parkinson’s disease and movement disorders rather than general wellness or activity tracking. The product combines five lightweight wearable monitoring devices that collect three-dimensional kinematic data with software intended to support clinical assessment and treatment decisions. This integrated hardware, mobile, cloud, and physician-dashboard model differentiates the company from point solutions that provide only patient apps, single-sensor measurements, or episodic clinic assessments. The company’s CE-marked Class IIa device status and quality-system credentials create a regulated-medical-device profile rather than a consumer wearable profile. Its 2023 Series A and reported employee range of 11–50 indicate an early commercial-stage specialist rather than a scaled global medtech platform.

Founded in 2015, PD Neurotechnology has followed a product-development path centered on converting movement-disorder research into a regulated monitoring system. The clearest funding inflection point came on Apr 25, 2023, when the company announced a €2.7 million Series A, approximately $2.96 million, led by Crimson International Investment with four additional investors. The financing followed the development of PDMonitor®, an integrated system spanning wearable sensors, a SmartBox, patient and caregiver mobile applications, secure cloud storage, and a physician-facing reporting tool. The company reports more than 10 years of research and development, CE marking as a Class IIa medical device, and production-related capabilities in Ioannina, Greece. These milestones suggest progression from technical validation toward clinical and commercial execution. The disclosed employee range of 11–50 and four listed current leadership positions indicate a compact organization.